Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
COVID-19
COVID-19 Daily Update
COVID-19 EventAnalyzer
COVID-19 Stories from Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Custom Solutions
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial team
About Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
English
日本語
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
NPS Pharmaceuticals
February 16, 2016
Zealand plays catch-up with Shire in short bowel syndrome
April 10, 2015
Shire shines as a post-AbbVie solo act
January 15, 2015
Mega-merger drought fails to impede record-breaking acquisition year
January 12, 2015
Natpara risk overshadows Shire’s NPS takeout
November 04, 2014
PD-1s make way for the next wave of blockbuster launches
October 16, 2014
Shabbvie is dead; long live Shire
October 10, 2014
Upcoming events: Rett data for Neuren while NPS awaits Natpara approval
September 22, 2014
Still unpartnered, but now worth a lot more
August 29, 2014
Upcoming events: FDA panels take on liraglutide and Natpara
July 22, 2014
Small-molecule launches hold their own
February 19, 2014
Vantage Point – Four-tier drug plans thrust affordability into spotlight
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 20, 2020
Vantage Pharma, Biotech & Medtech 2019 in Review
December 17, 2019
Vantage 2020 Preview
Editor's Picks
March 18, 2020
A Covid-19 treatment plan slowly emerges
March 11, 2020
Tiziana takes a deep breath and targets Covid-19
March 12, 2020
Estimating the cost of Covid-19 antiviral development
March 10, 2020
Few groups have developed Covid-19 diagnostics – but this will change
March 20, 2020
Clinical trial delays become reality as Covid-19 risk spreads
